Search Result
Results for "
muscular
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-101459
-
|
|
Others
|
Metabolic Disease
|
RTC13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-108753
-
|
AVI 4658
|
Others
|
Metabolic Disease
|
|
Eteplirsen (AVI 4658) is a synthetic antisense oligonucleotide. Eteplirsen can be used for Duchenne muscular dystrophy research .
|
-
-
- HY-132592A
-
|
WVE-210201 sodium
|
Others
|
Metabolic Disease
|
|
Suvodirsen sodium induces exon 51 skipping and has the potential for study Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-132592
-
|
WVE-210201
|
Others
|
Metabolic Disease
|
|
Suvodirsen (WVE-210201) is a oligonucleotide. Suvodirsen has the potential for study Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-P99588
-
|
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
-
- HY-122631
-
|
|
CDK
|
Others
|
|
TG693 is an orally active inhibitor of CLK1. TG693 regulates the mutated exon 31 of the dystrophin gene in vivo. TG693 is used in Duchenne muscular dystrophy (DMD) research .
|
-
-
- HY-132585A
-
|
Vesleteplirsen sodium
|
Others
|
Others
|
|
SRP-5051 sodium is a next-generation antisense oligonucleotide of peptide phosphorodiamidate morpholino oligomer (PPMO). SRP-5051 targeting exon 51 skipping in Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-132611A
-
|
SRP-4053 sodium
|
Others
|
Others
|
|
Golodirsen sodium is a phosphorodiamidate morpholino oligomer (PMO) that specifically targets exon 53 of dystrophin pre-mRNA. Golodirsen sodium can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-127137
-
|
Adenylosuccinate; Aspartyl adenylate
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD) .
|
-
-
- HY-132611
-
|
SRP-4053
|
Others
|
Others
|
|
Golodirsen (SRP-4053) is a phosphorodiamidate morpholino oligomer (PMO) that specifically targets exon 53 of dystrophin pre-mRNA. Golodirsen can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-150077
-
|
|
Others
|
Others
|
|
Utrophin modulator 1 is a potent utrophin modulator (upregulates utrophin protein levels), with an EC50 of 0.11 μM. Utrophin modulator 1 can be used in study of duchenne muscular dystrophy (DMD) .
|
-
-
- HY-127137A
-
|
Adenylosuccinate tetraammonium; Aspartyl adenylate tetraammonium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Adenylosuccinic acid tetraammonium (Adenylosuccinate; Aspartyl adenylate) is an orally active purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid tetraammonium can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid tetraammonium has the potential for the study of duchenne muscular dystrophy(DMD) .
|
-
-
- HY-109017
-
-
-
- HY-161050
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
YSR734 (Compound 21) is a covalent HDAC inhibitor with IC50 values of 110 nM, 154 nM, and 143 nM for HDAC1, HDAC2, and HDAC3, respectively. YSR734 can induce apoptosis in leukemia cells. YSR734 can induce myoblast differentiation and is used in the study of Duchenne muscular dystrophy .
|
-
-
- HY-134577
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
Clorprenaline is a potent agonist of β2-adrenergic. Clorprenaline promotes animal muscular mass growth and decreases fat accumulation. Clorprenaline is a potential new lean meat-boosting feed additive .
|
-
-
- HY-17614
-
|
SMT C1100; BMN 195; VOX-C1100
|
Cytochrome P450
|
Others
|
|
Ezutromid (SMT C1100) is a first-in-class, orally active benzoxazole utrophin modulator with an EC50 of 0.91 μM. Ezutromid can be used for the research Duchenne muscular dystrophy (DMD). Ezutromid inhibits CYP1A2 enzymic activity in human liver microsomes (HLM) with an IC50 of 5.4 μM .
|
-
-
- HY-150078
-
|
|
Others
|
Others
|
|
OX01914 is a water-solube and permeable utrophin modulator (upregulates utrophin protein levels), with an EC50 of 20.5 μM. OX01914 can be used in study of duchenne muscular dystrophy (DMD) .
|
-
-
- HY-134377
-
|
ASP0367; MA-0211
|
PPAR
|
Metabolic Disease
|
|
Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b) .
|
-
-
- HY-132584A
-
|
SRP-4045 sodium
|
Others
|
Others
|
|
Casimersen sodium is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen sodium binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen sodium can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-14415
-
|
|
REV-ERB
|
Neurological Disease
Metabolic Disease
|
|
SR8278 is a REV-ERBα antagonist and inhibits the REV-ERBα transcriptional repression activity with an EC50 of 0.47 μM. SR8278 is used to regulate the metabolism in organisms and study biological rhythm. SR8278 also can be used for the research of Duchenne muscular dystrophy and Alzheimer's disease .
|
-
-
- HY-132584
-
|
SRP-4045
|
Others
|
Others
|
|
Casimersen (SRP-4045) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-152219
-
|
|
CDK
|
Infection
Cancer
|
|
CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC50 value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza .
|
-
-
- HY-132586
-
|
NS-065/NCNP-01
|
Nucleoside Antimetabolite/Analog
|
Metabolic Disease
|
|
Viltolarsen (NS-065/NCNP-01) is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
-
- HY-124713
-
|
|
DNA/RNA Synthesis
|
Neurological Disease
|
|
ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .
|
-
-
- HY-111520
-
|
|
DNA/RNA Synthesis
|
Neurological Disease
|
|
NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC50 of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .
|
-
-
- HY-132586A
-
|
NS-065/NCNP-01 sodium
|
Nucleoside Antimetabolite/Analog
|
Metabolic Disease
|
|
Viltolarsen (NS-065/NCNP-01) sodium is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen sodium binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen sodium has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
-
- HY-19620
-
Branaplam
Maximum Cited Publications
9 Publications Verification
LMI070; NVS-SM1
|
DNA/RNA Synthesis
Potassium Channel
|
Cancer
|
|
Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .
|
-
-
- HY-19620A
-
|
LMI070 hydrochloride; NVS-SM1 hydrochloride
|
DNA/RNA Synthesis
Potassium Channel
|
Cancer
|
|
Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .
|
-
-
- HY-153403
-
|
|
Others
|
Others
|
|
Activated A Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153404
-
|
|
Others
|
Others
|
|
Activated C Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153405
-
|
|
Others
|
Others
|
|
Activated DPG Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153406
-
|
|
Others
|
Others
|
|
Activated T Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153407
-
|
|
Others
|
Others
|
|
NCP2 Anchor can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 52 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153402
-
|
|
Others
|
Others
|
|
Activated EG3 Tail can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-B1104
-
|
(±)-Indoprofe
|
Others
|
Inflammation/Immunology
|
|
Indoprofen is a non-steroidal anti-inflammatory drug, provide insight into treatments for spinal muscular atrophies.
|
-
-
- HY-B1079
-
|
|
Others
|
Inflammation/Immunology
|
|
Suxibuzone is a drug used for joint and muscular pain, is a prodrug of the non steroidal anti inflammatory drug Phenylbutazone.
|
-
-
- HY-101792
-
RG7800
5 Publications Verification
RO6885247
|
DNA/RNA Synthesis
|
Others
|
|
RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.
|
-
-
- HY-153324
-
|
|
Others
|
Others
|
|
PS220 (sodium) is an antisense RNA oligonucleotides. PS220 (sodium) can be used for research of treating muscular dystrophy .
|
-
-
- HY-112633
-
|
|
DNA/RNA Synthesis
|
Others
|
|
SMN-C3 is an orally active SMN2 splicing modulator and has the potential to treat spinal muscular atrophy (SMA).
|
-
-
- HY-D1005A25
-
|
PEG-PPG-PEG, 5750 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 403 P123 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 5750. Poloxamer 403 P123 exhibits muscular toxicity .
|
-
-
- HY-B0262S
-
|
|
Sodium Channel
|
Metabolic Disease
|
|
Methocarbamol-d5 is deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel[1].
|
-
-
- HY-W272699
-
|
|
Others
|
Metabolic Disease
|
|
Utrophin activator-1 (compound 3) is an utrophin upregulator with an EC50 of 1.8 μM. Utrophin activator-1 can be used for Duchenne muscular dystrophy research .
|
-
-
- HY-145724
-
|
Kyndrisa; GSK2402968A; PRO051
|
Others
|
Others
|
|
Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.
|
-
-
- HY-109134
-
|
TAS-205 free base
|
Prostaglandin Receptor
|
Metabolic Disease
|
|
Pizuglanstat (compound 3) is a prostaglandin D synthase inhibitor with an IC50 of 76 nM for human hematopoietic prostaglandin D synthases (H-PGDS). Pizuglanstat can be used for myodegenerative disease research, such as muscular dystrophy .
|
-
-
- HY-107901
-
|
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
|
-
-
- HY-N1072
-
|
|
|
|
|
Wilforgine is a bioactive sesquiterpene alkaloid in Tripterygium wilfordii Hook. F. Wilforgine can induce microstructural and ultrastructural changes in the muscles of Mythimna separata larvae, and the sites of action are proposed to be calcium receptors or channels in the muscular system .
|
-
-
- HY-101792A
-
|
RO6885247 tetrahydrochloride
|
DNA/RNA Synthesis
|
Neurological Disease
|
|
RG7800 hydrochloride is an orally active SMN2 splicing modulator, with EC1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; RG7800 hydrochloride has the potential to treat spinal muscular atrophy.
|
-
-
- HY-150237
-
|
|
Others
|
Others
|
|
FITC-labeled Drisapersen (sodium) is Drisapersen labeled with FITC. Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.
|
-
-
- HY-48959
-
|
|
Integrin
|
Metabolic Disease
|
|
α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. α7β1 integrin modulator-1 has the potential for the research of muscular dystrophy .
|
-
-
- HY-18102
-
|
|
Androgen Receptor
|
Others
|
|
GLPG0492 is a non-steroidal selective androgen receptor modulator (potency 12 nM). GLPG0492 has the potential for the research of musculo-skeletal diseases such as sarcopenia and cachexia .
|
-
- HY-B0262
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .
|
-
- HY-121705
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Propionyl-L-carnitine is a carnitine derivative and has a high affinity for muscular carnitine transferase. Propionyl-L-carnitine increases cellular carnitine content, thereby allowing free fatty acid transport into the mitochondria. Propionyl-L-carnitine alleviates the symptoms of PAD through a metabolic pathway, thereby improving exercise performance .
|
-
- HY-114739
-
|
|
PPAR
|
Metabolic Disease
|
|
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC50s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) .
|
-
- HY-W015828
-
|
RGX-202; 3-Guanidinopropionic acid
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
Ompenaclid (RGX-202) is an oral small-molecule SLC6A8 transporter inhibitor. Ompenaclid robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. Ompenaclid can be used for the research of cancer and duchenne muscular dystrophy .
|
-
- HY-B1139S
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
Tolperisone-d10 (hydrochloride) is the deuterium labeled Tolperisone hydrochloride. Tolperisone hydrochloride is a centrally acting muscle relaxant, is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.
|
-
- HY-112980
-
|
|
DNA/RNA Synthesis
|
Inflammation/Immunology
|
|
Nusinersen is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .
|
-
- HY-112980A
-
|
|
DNA/RNA Synthesis
|
Inflammation/Immunology
|
|
Nusinersen sodium is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .
|
-
- HY-B0262S1
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Methocarbamol-d3 is the deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research[1][2][3].
|
-
- HY-B0262S2
-
|
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Methocarbamol- 13C,d3 is the 13C- and deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research[1][2][3].
|
-
- HY-111055
-
|
|
GSK-3
|
Neurological Disease
|
|
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .
|
-
- HY-D1005A21
-
|
PEG-PPG-PEG, 6500 (Averag)
|
Biochemical Assay Reagents
Bacterial
|
Infection
|
|
Poloxamer 335 P105 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 6500. Poloxamer 335 P105 exhibits antimicrobial activity, that inihibits 86% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 334 P104 exhibits muscular toxicity. Poloxamer 334 P104 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-124648
-
|
|
DNA/RNA Synthesis
|
Inflammation/Immunology
|
|
SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research .
|
-
- HY-16361A
-
|
CGP3466B; CGP3446 maleate; TCH346 maleate
|
|
|
|
Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease . Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-153369
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
Neurological Disease
|
|
BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
|
-
- HY-136340
-
|
|
Glucocorticoid Receptor
NF-κB
|
Metabolic Disease
Inflammation/Immunology
|
|
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is an intermediate of delta 9,11 steroids synthesis, for example, Vamorolone (HY-109017). The delta 9,11 steroids are modifications of glucocorticoids and has anti-inflammatory properties. The delta 9,11 steroids are agents for protection against cell damage (lipid peroxidation) and inhibition of neovascularization .
|
-
- HY-120508
-
|
AN-9; Pivalyloxymethyl butyrate
|
HDAC
Bcr-Abl
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties .
|
-
- HY-147332
-
|
|
Liposome
|
Neurological Disease
|
|
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .
|
-
-
-
HY-L086
-
|
|
2228 compounds
|
|
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.
MCE offers a unique collection of 2228 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.
|
| Cat. No. |
Product Name |
Type |
-
- HY-147332
-
|
|
Drug Delivery
|
|
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .
|
-
- HY-D1005A25
-
|
PEG-PPG-PEG, 5750 (Averag)
|
Co-solvents
|
|
Poloxamer 403 P123 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 5750. Poloxamer 403 P123 exhibits muscular toxicity .
|
-
- HY-D1005A21
-
|
PEG-PPG-PEG, 6500 (Averag)
|
Co-solvents
|
|
Poloxamer 335 P105 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 6500. Poloxamer 335 P105 exhibits antimicrobial activity, that inihibits 86% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 334 P104 exhibits muscular toxicity. Poloxamer 334 P104 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-121705
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Propionyl-L-carnitine is a carnitine derivative and has a high affinity for muscular carnitine transferase. Propionyl-L-carnitine increases cellular carnitine content, thereby allowing free fatty acid transport into the mitochondria. Propionyl-L-carnitine alleviates the symptoms of PAD through a metabolic pathway, thereby improving exercise performance .
|
-
- HY-W019878
-
|
β-Lipotropin 61-91
|
Peptides
|
Cardiovascular Disease
Neurological Disease
|
|
β-Endorphin, rat (β-Lipotropin 61-91), a neuropeptide, is involved in cardiovascular regulation. β-Endorphin, rat induces marked, prolonged muscular rigidity and immobility similar to a catatonic state in rats .
|
-
- HY-P3712
-
|
|
Peptides
|
Cardiovascular Disease
Neurological Disease
|
|
Cardioexcitatory peptide 1 is a cardioexcitatory neuropeptide, can be isolated from Achatina atria. Cardioexcitatory peptide 1 has potent cardio-excitatory action on the hearts and also modifies the motility of muscular tissues and neural activities .
|
-
- HY-P5240
-
|
|
Peptides
|
Others
|
|
Acetyl tripeptide-30 citrulline is a bioactive peptide with anti-wrinkle effect and has been reported used as a cosmetic ingredient .
|
-
- HY-P1360
-
|
|
Peptides
|
Metabolic Disease
|
|
H-D-MeAla-EtVaI-VaI-MeLeu-AIa-D-AIa-MeLeu-MeLeu-MeVaI-MeBmt(OAc)-Abu-O-CH2-CH2-NHMe is a nonimmunosuppressive cyclosporin A derivative. H-D-MeAla-EtVaI-VaI-MeLeu-AIa-D-AIa-MeLeu-MeLeu-MeVaI-MeBmt(OAc)-Abu-O-CH2-CH2-NHMe has the potential for the research of congenital muscular dystrophy .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99441
-
|
SRK-015
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
|
-
- HY-P99518
-
|
BMS 986089; RG 6206; RO 7239361
|
Inhibitory Antibodies
|
Others
|
|
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
|
-
- HY-P99370
-
|
LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab)
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
-
- HY-P99588
-
|
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
- HY-P99857
-
|
PF-06252616
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0262S1
-
|
|
|
Methocarbamol-d3 is the deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research[1][2][3].
|
-
-
- HY-B0262S
-
|
|
|
Methocarbamol-d5 is deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel[1].
|
-
-
- HY-B1139S
-
|
|
|
Tolperisone-d10 (hydrochloride) is the deuterium labeled Tolperisone hydrochloride. Tolperisone hydrochloride is a centrally acting muscle relaxant, is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.
|
-
-
- HY-B0262S2
-
|
|
|
Methocarbamol- 13C,d3 is the 13C- and deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research[1][2][3].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
